<p>The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.</p>
Braveheart secures $185M to advance challenger to Bristol Myers heart drug
BioPharma Dive Oncology | | Ben Fidler
Topics: blood-cancer, cervical-cancer, breakthrough-drugs